Squarepoint Ops LLC Prelude Therapeutics Inc Transaction History

Squarepoint Ops LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.69 - $4.37 $17,391 - $44,971	10,291 Added 53.8%	29,418 $125,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $85,115 - $155,311	19,127 New	19,127 $86,000
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $46,864 - $88,455	-11,716 Reduced 37.39%	19,618 $102,000
Q1 2022 May 16, 2022	SELL	$6.9 - $13.22 $119,597 - $229,142	-17,333 Reduced 35.62%	31,334 $216,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $578,650 - $1.54 Million	48,667 New	48,667 $606,000
Q1 2021 May 17, 2021	SELL	$39.27 - $91.68 $813,910 - $1.9 Million	-20,726 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$28.81 - $88.94 $960,525 - $2.97 Million	-33,340 Reduced 61.67%	20,726 $1.48 Million
Q3 2020 Nov 16, 2020	BUY	$26.2 - $30.13 $1.42 Million - $1.63 Million	54,066 New	54,066 $1.63 Million

35.9M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $42.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.